BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Corica D, Romano C. Biological Therapy in Pediatric Inflammatory Bowel Disease: A Systematic Review. J Clin Gastroenterol. 2017;51:100-110. [PMID: 27636407 DOI: 10.1097/mcg.0000000000000696] [Cited by in Crossref: 27] [Cited by in F6Publishing: 6] [Article Influence: 5.4] [Reference Citation Analysis]
Number Citing Articles
1 Guariso G, Gasparetto M. Treating children with inflammatory bowel disease: Current and new perspectives. World J Gastroenterol 2017; 23(30): 5469-5485 [PMID: 28852307 DOI: 10.3748/wjg.v23.i30.5469] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 21] [Article Influence: 4.6] [Reference Citation Analysis]
2 Zibandeh N, Genc D, Duran Y, Banzragch M, Sokwala S, Goker K, Atug O, Akkoç T. Human dental follicle mesenchymal stem cells alleviate T cell response in inflamed tissue of Crohn's patients. Turk J Gastroenterol 2020;31:400-9. [PMID: 32519960 DOI: 10.5152/tjg.2020.19358] [Reference Citation Analysis]
3 van Straalen JW, Krol RM, Giancane G, Panaviene V, Ailioaie LM, Doležalová P, Cattalini M, Susic G, Sztajnbok F, Maritsi D, Constantin T, Sawhney S, Rygg M, Oliveira SK, Nordal EB, Saad-Magalhaes C, Rubio-Perez N, Jelusic M, de Roock S, Wulffraat NM, Ruperto N, Swart JF; Paediatric Rheumatology International Trials Organisation (PRINTO). Increased incidence of inflammatory bowel disease on etanercept in juvenile idiopathic arthritis regardless of concomitant methotrexate use. Rheumatology (Oxford) 2021:keab678. [PMID: 34508559 DOI: 10.1093/rheumatology/keab678] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Ramos Pinheiro R, Diamantino F, Cabete J, Brasileiro A, Baptista J, Lopes MJP. Switching biologics in severe pediatric psoriasis: a retrospective analysis. Int J Dermatol 2017;56:1461-4. [DOI: 10.1111/ijd.13752] [Cited by in Crossref: 5] [Article Influence: 1.0] [Reference Citation Analysis]
5 Jochmann A, Trachsel D, Hammer J. Inflammatory bowel disease and the lung in paediatric patients. Breathe (Sheff) 2021;17:200269. [PMID: 34295391 DOI: 10.1183/20734735.0269-2020] [Reference Citation Analysis]
6 Salvador-Martín S, Melgarejo-Ortuño A, López-Fernández LA. Biomarkers for Optimization and Personalization of Anti-TNFs in Pediatric Inflammatory Bowel Disease. Pharmaceutics 2021;13:1786. [PMID: 34834201 DOI: 10.3390/pharmaceutics13111786] [Reference Citation Analysis]
7 Aardoom MA, Veereman G, de Ridder L. A Review on the Use of Anti-TNF in Children and Adolescents with Inflammatory Bowel Disease. Int J Mol Sci 2019;20:E2529. [PMID: 31126015 DOI: 10.3390/ijms20102529] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 5.7] [Reference Citation Analysis]
8 Kowalska-Duplaga K, Kapusta P, Gosiewski T, Sroka-Oleksiak A, Ludwig-Słomczyńska AH, Wołkow PP, Fyderek K. Changes in the Intestinal Microbiota Are Seen Following Treatment with Infliximab in Children with Crohn's Disease. J Clin Med 2020;9:E687. [PMID: 32143438 DOI: 10.3390/jcm9030687] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
9 Szymanska E, Dadalski M, Sieczkowska-Golub J, Jarzebicka D, Meglicka M, Osiecki M, Wiernicka A, Lebensztejn DM, Korczowski B, Kierkus J. Premedication Does Not Influence the Incidence of Infliximab Infusion Reactions in Pediatric Patients with Inflammatory Bowel Disease-A Single Center Case-Control Study. J Clin Med 2021;10:3177. [PMID: 34300342 DOI: 10.3390/jcm10143177] [Reference Citation Analysis]